Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1674416 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $47.64Day +0.19%Mkt cap $4.6B1Y −19.3%Off 52W high −39.3%Vol (1Y) 58.0%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,586 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest20.5% of sh out |
| Days to cover11.6d |
| 13F net flow (QoQ)−5.64% |
| Top-10 13F concentration60.1% |
| Next report (est.)2026-08-03 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$4.1M |
| Earnings (TTM)-$568.5M |
| ROE−30.2% |
| Net margin−16569.8% |
| ROIC−32.7% |
| Sales growth 3Y43.1% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−9.2% |
| 1Y−19.3% |
| 3Y−16.9% |
| 5Y−60.0% |
| Since incept. (ann.)+3.4% |
Total return through 2026-07-29 · series begins 2020-04-01. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)58.0% |
| Ann. volatility (3Y)58.6% |
| Sharpe (1Y)−0.22 |
| Sharpe (3Y)0.19 |
| Max drawdown (1Y)−42.3% |
| Max drawdown (3Y)−64.9% |
| Beta (3Y vs SPY)3.09 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| ARK Investment Management LLC | 11.3M | $538M | 11.79% | +7.5% |
| BlackRock, Inc. | 7.7M | $365M | 8.00% | +2.3% |
| Orbis Allan Gray Ltd | 6.1M | $290M | 6.36% | +2.6% |
| Capital World Investors | 4.7M | $225M | 4.92% | new |
| STATE STREET CORP | 4.0M | $189M | 4.15% | +6.1% |
| GSK plc | 3.2M | $153M | 3.36% | +0.0% |
| T. Rowe Price Investment Management, Inc. | 3.0M | $140M | 3.08% | −41.8% |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4M | $113M | 2.48% | +5.7% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-04 | −$1.28 | — | $1.5M | +68.6% |
| 2025-12-31 | 2026-02-12 | — | — | $864,000 | −97.6% |
| 2025-09-30 | 2025-11-10 | −$1.17 | — | $889,000 | +47.7% |
| 2025-06-30 | 2025-08-04 | −$2.40 | — | $892,000 | +72.5% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-03 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Grant 100%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
